Efficacy Multicentre Trial of ImmunoTherapy Vaccination With Abagovomab to Treat Ovarian Cancer Patients (MIMOSA)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00418574|
Recruitment Status : Terminated (No benefit on primary end point (RFS); no rationale to collect survival data)
First Posted : January 5, 2007
Results First Posted : November 18, 2011
Last Update Posted : November 24, 2011
|Condition or disease||Intervention/treatment||Phase|
|Ovarian Cancer||Biological: Abagovomab Biological: Placebo||Phase 2 Phase 3|
Standard initial treatment of ovarian cancer patients includes both surgery and chemotherapy which in the vast majority of cases achieves the disappearance of ovarian cancer lesions. This status, called "clinical remission" which means having no evidence of cancer on CT scan or physical examination needs to be carefully follow up in order to confirm the maintenance of the remission status or to early detect if the cancer grows again and then start a new chemotherapy. At present, no approved therapies exist for the maintenance treatment of patients who achieved the clinical remission.
This trial aims to evaluate if the repeated vaccination with Abagovomab creates an immunoresponse which is able to fight the cancer cells thus keeping the remission status as long as possible and help patients live disease-free and longer.
Patients who achieve the remission status after chemotherapy will be screened for study participation and if they meet the criteria for inclusion they will start to receive a single subcutaneous injection every 2 weeks (for the first 4 doses - induction phase) and then every 4 weeks (maintenance phase). The duration of treatment is up to approximately 4 years or it will be stopped in case relapse occurs.
In order to evaluate the real benefit of vaccination, the experimental treatment includes Abagovomab (the active drug) or placebo (the vehicle only, without drug), with a double chance to receive Abagovomab. Assignment of Abagovomab or placebo will be done by a computerised system and nobody in the study will know which treatment has been allocated until study end.
Patients will be visited every 4 weeks and will undergo CT scan of pelvis and abdomen every 12 weeks in order to confirm the remission status or to early detect if relapse eventually occurs. This will be done in blind condition (i.e. without being aware which treatment the patient is going to receive) for the first part of the study which is expected to last four years. After then the overall status of patient will continue to be monitored by phone contact for additional five years.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||888 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Triple (Participant, Care Provider, Investigator)|
|Official Title:||A Randomised,Double Blind, Placebo Controlled, Multicentre Trial of Abagovomab Maintenance Therapy in Patients With Epithelial Ovarian Cancer After Complete Response to First Line Chemotherapy|
|Study Start Date :||December 2006|
|Actual Primary Completion Date :||December 2010|
|Actual Study Completion Date :||June 2011|
2 mg/ml SC (subcutaneously)
|Placebo Comparator: Placebo||
2 mg/ml SC (subcutaneously)
- Recurrence Free Survival Evaluated by Clinical Event Adjudication Committee (CEAC) [ Time Frame: Every 12 weeks up to recurrence or up to 3 months after last administered dose ]The Recurrence free survival correspond to the time from date of randomization to documented disease recurrence or death. Disease recurrence is defined as the appearance of any lesion or development of tumor-related symptoms evaluated by medical examination and must be confirmed by a documented CT scan.
- Overall Survival [ Time Frame: 2 years ]2 years survival rate
- Safety [ Time Frame: Along treatment administration and up to double blind observation period. i.e. for each patient after the first dose administration till the f inal study visit, or within 12 weeks of the last dose ]
Safety was analyzed in all patients who received at least 1 dose administration.
Adverse event (AE) are defined as events which started on or after the first dose of study medication and on or before the date of the final study visit, or within 12 weeks of the last dose if the final study visit was not performed.
- Time Course of Immunoresponse [ Time Frame: at baseline, at week 10 after first dose administration and at final study visit (at week 4 or week 12 after the last administered dose, as appropriate) ]Time course of immunologic parameters (anti-anti-idiotypic antibody - Ab3) will be assessed in all patients, by comparing levels at baseline (week 0), at week 10 after first dose administration and at end of treatment (at week 4 or week 12 after the last administered dose, as appropriate).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00418574
|Study Chair:||Jacobus Pfisterer, MD||AGO-OVAR, Ovarian Cancer Study Group, Germany; Ubbo-Emmius-Klinik gGmbH Aurich, Germany|
|Principal Investigator:||Paul Sabbatini, MD||Memorial Sloan-Kettering Cancer Centre- NY|
|Principal Investigator:||Jonathan Berek, MD||COGI (Cooperative Ovarian Cancer Group for Immunotherapy); Dept Obstetrics and Gynecology, Stanford CA|
|Principal Investigator:||Giovanni Scambia, MD||Universtita' Cattolica del Sacro Cuore, Dipartimento di Oncologia - Roma, Italy|
|Principal Investigator:||Antonio Casado, MD||Hospital Clinico San Carlos, Servicio de Oncología Medica - Madrid, Spain|
|Principal Investigator:||Anna Pluzanska, MD||Klinika Chemioterapii Nowotworów Akademii Medycznej w Łodzi, Regionalny Osrodek Onkologiczny - Lodz, Poland|
|Principal Investigator:||Karel Cwiertka, MD||Onkologická klinika Fakultni Nemocnice Olomouc, Czech Republic|
|Principal Investigator:||Tamás Pintér, MD||Petz Aladar Megyei Oktató Kórház, Onkoradiológia - Győr, Hungary|
|Principal Investigator:||Eric Pujade-Lauraine, MD||Hôpital Hotel Dieu - Paris, France|